Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide + hydroxychloroquine for primary Sjogren's syndrome
NL-OMON45101Phase 3Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of leflunomide and hydroxychloroquine in Sjögren's syndrome (SS) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in ESSDAI score from baseline to week 24. Started Mar 2016; status: active, not recruiting.
02
Drugs
leflunomidehydroxychloroquine
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on NL-OMON45101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45101.